Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SAT-3247

Small molecule · Inhibitor of AP2-associated kinase 1 (AAK1) · developed by Satellos Bioscience

Phase 2 Most advanced trial
MSLE Developer
1 Registered trials

What is SAT-3247?

SAT-3247 is an oral tablet that selectively inhibits AAK1, a kinase, to restore asymmetric satellite cell division. This is intended to increase muscle progenitor cell production, improve muscle regeneration and enhance muscle function. It is being studied in Duchenne muscular dystrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
AP2-associated kinase 1 (AAK1)
Mechanism
Inhibitor of AP2-associated kinase 1 (AAK1)
Pathways
asymmetric satellite cell division, muscle progenitor cell production, muscle regeneration
Therapy area
Neurology
Developer
Satellos Bioscience, Inc. (MSLE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07287189 Phase 2 Duchenne Muscular Dystrophy Active not recruiting MSLE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DMDDuchenneDuchenne Muscular DystrophyMuscular DystrophiesNeuromuscular Diseases

Other drugs acting on AAK1

More from Satellos Bioscience

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the MSLE page.

Follow MSLE, the company behind SAT-3247

See MSLE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MSLE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.